Lenvatinib
VEGFR kinase inhibitor / A potent inhibitor of VEGFR2 and R3, IC50s=4.0 and 5.2 nM respectively.1 Also inhibits VEGFR1, FGFR1, PDGFR3b and Kit, IC50s=22, 46, 39 and 100 nM respectively.1 Suppresses lymph node and lung metastasis in human mammary breast tumor model.2 Suppresses tumor cell migration and invasion.3 Inhibits angiogenesis.4
Biochemicals & reagents
417716-92-8
E7080
1) Matsui et al. (2008), E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition; Int. J. Cancer, 122 664 2) Matsui et al. (2008), Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R)2 and VEGF-R3 kinase; Clin. Cancer Res., 14 5459 3) Glen et al. (2011), E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion; BMC Cancer, 11 309 4) Yamamoto et al. (2014), Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage; Vasc. Cell, 6 18
-20°C
TARGET: Kinase -- PATHWAY: Cell migration -- RESEARCH AREA: Angiogenesis -- DISEASE AREA: Cancer